Emgality administration3


  • Inspect the prefilled syringe and the medicine. Do not use the prefilled syringe and dispose of it if: it looks damaged, the expiration date printed on the label has passed, or the medicine is cloudy, discolored, has small particles, or is frozen
  • Choose an area for injection: abdomen or thigh if self-injecting, and buttocks or back of upper arm if another person is injecting. Be sure to choose a different site (even within an area) for each injection
  • Clean the site with an alcohol wipe and let it dry before injecting

The 3 key administration steps3

Please review the full Instructions for Use with your patients to ensure they understand how to properly administer Emgality.

3 Key Administration Steps
3 Key Administration Steps
3 Key Administration Steps
Telephone icon

Telephone injection training and an Injection how-to video are available to help guide your patients through self-administration.

Questions? Call 1-833-EMGALITY (1-833-364-2548).

Indications and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.